This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Milsom I, Wickstrøm J, Poulsen PB.Cost-effectiveness analysis of solifenacin flexible dosing in patients with overactive bladder symptoms in four Nordic countries. Value in Health 9: A389 (plus poster) abstr. PUK16, No. 6, Nov-Dec 2006
Rights and permissions
About this article
Cite this article
Solifenacin worth it for OAB in Nordic countries. Pharmacoecon. Outcomes News 518, 4 (2006). https://doi.org/10.2165/00151234-200605180-00011
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200605180-00011